Ophthalmoscopes
Jan 30, 2025
Norlase’s LYNX Receives FDA and CE Approval for Clinical Use; FDA Approves Imperative Care’s Zoom System; Lunit AI Enhances Predictive Accuracy for HER2-Targeted Therapy in Metastatic Colorectal Cancer; ImmunoMet Reports New Insights from Phase 1b Study of Lixumistat in Pancreatic Cancer; Lumicell Announces U.S. Launch of LumiSystem; Inventia Life Science Introduces RASTRUM™ Allegro to Advance High-Throughput 3D Cell Culture
Norlase Received FDA 510(k) Clearance and CE Mark for LYNX™ Indirect Laser Ophthalmoscope with Pattern Tracking On January 27, 2025, Norlase, a leading global manufacturer of ophthalmic lasers developing next-generation laser solutions, announced the commercial launch and receipt of FDA 510(k) clearance and CE M...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
